PTC Therapeutics announced the expansion of its European label for translarna (ataluren).

Ataluren restores dystrophin production in individuals with Duchenne caused by a nonsense mutation. This treatment is only available in Europe. The label expansion now allows patients who have lost their ability to walk to continue to use ataluren.

Read the full press release here.

Ataluren has not been approved by Health Canada, however, PTC is currently recruiting in Ontario and British Columbia for their long-term study. If you are interested in learning more about this trial click here. If you are interested to learn more about ataluren, speak to your neuromuscular team.

If you have any questions about this or any other news releases from Defeat Duchenne Canada please contact:

Nicola Worsfold Director of Research and Advocacy nicola@defeatduchenne.ca